Euan Menzies replaces Jim Datin as BioAgilytix CEO

21 June 2022

Privately-held contract research organization BioAgilytix Labs has announced the appointment of Euan Menzies as chairman and chief executive.

Mr Menzies is replacing Jim Datin, who has served as chief executive at the North Carolina company since 2013, during which time he has been credited for leading the firm through a period of exponential growth while maintaining impressive customer satisfaction and employee retention rankings.

Mr Datin, who will continue to serve as a non-executive member of the board of directors, said it had been an “incredible experience to serve as chief executive during this period of growth and transformation.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK